Trials / Unknown
UnknownNCT03692520
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
Recombinant Anti-EGFR Monoclonal Antibody（SCT200）in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced solid tumors treated after failure of standard therapy.
Detailed description
This open label, multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in advanced solid tumors (gastric/gastroesophageal junction cancer, hepatocellular carcinoma,pancreatic cancer,gallbladder cancer/bile duct cancer，renal cell carcinoma，ovarian cancer，or other advanced solid tumor) treated with anti-EGFR monoclonal antibody SCT200.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCT200 | Recombinant Anti-EGFR Monoclonal Antibody （SCT200） |
Timeline
- Start date
- 2018-09-30
- Primary completion
- 2019-11-30
- Completion
- 2020-04-30
- First posted
- 2018-10-02
- Last updated
- 2018-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03692520. Inclusion in this directory is not an endorsement.